Spyre Therapeutics

Yahoo Finance • 12 days ago

Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended... Full story

Yahoo Finance • 22 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the stan... Full story

Yahoo Finance • 25 days ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investig... Full story

Yahoo Finance • last month

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammato... Full story

Yahoo Finance • last month

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for... Full story

Yahoo Finance • 3 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 4 months ago

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 4 months ago

Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28

* Spyre Therapeutics press release [https://seekingalpha.com/pr/20190026-spyre-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SYRE [https://seekingalpha.com/symbol/SYRE]): Q2 GAAP EPS of -$0.49... Full story

Yahoo Finance • 4 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through... Full story

Yahoo Finance • 5 months ago

Spyre reports results from early stage TL1A antibody trials

[3d illustration proteins] Design Cells/iStock via Getty Images * Spyre Therapeutics (NASDAQ:SYRE [https://seekingalpha.com/symbol/SYRE]) reported updates from its initial early stage studies involving SPY002 and SPY072, the company's n... Full story

Yahoo Finance • 5 months ago

Spyre reports positive results for anti-TL1A antibodies in trials

WALTHAM, Mass. - Spyre Therapeutics (NASDAQ:SYRE), a clinical-stage biotech company currently valued at $1.04 billion, announced positive interim Phase 1 results for its investigational extended half-life monoclonal antibodies SPY002 and S... Full story